RVMD.NASDAQRevolution Medicines, INC

Form 4: Revolution Medicines Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)

📋All filings for Revolution Medicines, INC
🔒Login to Follow

Mark A Goldsmith, See Remarks and a Director of Revolution Medicines, Inc., sold 86,000 shares of common stock on August 21, 2026.

Summary

  • Option exercise/conversion: acquired 80,000 Common Stock at $4.73 ($378,400) on August 21, 2026; holds 347,330 after (Direct).
  • Open-market sale: disposed of 5,128 Common Stock at $207.23 ($1,062,691) on August 21, 2026; holds 342,202 after (Direct).
  • Open-market sale: disposed of 24,917 Common Stock at $208.37 ($5,191,948) on August 21, 2026; holds 317,285 after (Direct).
  • Open-market sale: disposed of 35,938 Common Stock at $209.26 ($7,520,440) on August 21, 2026; holds 281,347 after (Direct).
  • Open-market sale: disposed of 3,813 Common Stock at $210.25 ($801,670) on August 21, 2026; holds 277,534 after (Direct).
  • Open-market sale: disposed of 6,583 Common Stock at $211.33 ($1,391,206) on August 21, 2026; holds 270,951 after (Direct).
  • Open-market sale: disposed of 3,621 Common Stock at $212.08 ($767,933) on August 21, 2026; holds 267,330 after (Direct).
  • Open-market sale: disposed of 190 Common Stock at $207.25 ($39,377) on August 21, 2026; holds 64,234 after (Indirect).
  • Open-market sale: disposed of 951 Common Stock at $208.36 ($198,155) on August 21, 2026; holds 63,283 after (Indirect).
  • Open-market sale: disposed of 1,351 Common Stock at $209.28 ($282,739) on August 21, 2026; holds 61,932 after (Indirect).
  • Open-market sale: disposed of 136 Common Stock at $210.40 ($28,615) on August 21, 2026; holds 61,796 after (Indirect).
  • Open-market sale: disposed of 245 Common Stock at $211.47 ($51,809) on August 21, 2026; holds 61,551 after (Indirect).
  • Open-market sale: disposed of 127 Common Stock at $212.06 ($26,932) on August 21, 2026; holds 61,424 after (Indirect).
  • Open-market sale: disposed of 177 Common Stock at $207.25 ($36,684) on August 21, 2026; holds 64,247 after (Indirect).
  • Open-market sale: disposed of 937 Common Stock at $208.36 ($195,234) on August 21, 2026; holds 63,310 after (Indirect).
  • Open-market sale: disposed of 1,405 Common Stock at $209.27 ($294,019) on August 21, 2026; holds 61,905 after (Indirect).
  • Open-market sale: disposed of 126 Common Stock at $210.40 ($26,511) on August 21, 2026; holds 61,779 after (Indirect).
  • Open-market sale: disposed of 229 Common Stock at $211.46 ($48,425) on August 21, 2026; holds 61,550 after (Indirect).
  • Open-market sale: disposed of 126 Common Stock at $212.06 ($26,720) on August 21, 2026; holds 61,424 after (Indirect).
  • Option exercise/conversion: disposed of 80,000 Stock Option (Right to Buy) on August 21, 2026; holds 344,085 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $17,991,107 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Mark A Goldsmith — Director, Officer (See Remarks)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-08-21Option exercise/conversionCommon Stock80,000$5$378.4K347,330
2026-08-21Open-market saleCommon Stock5,128$207$1.1M342,202
2026-08-21Open-market saleCommon Stock24,917$208$5.2M317,285
2026-08-21Open-market saleCommon Stock35,938$209$7.5M281,347
2026-08-21Open-market saleCommon Stock3,813$210$801.7K277,534
2026-08-21Open-market saleCommon Stock6,583$211$1.4M270,951
2026-08-21Open-market saleCommon Stock3,621$212$767.9K267,330
2026-08-21Open-market saleCommon Stock190$207$39.4K64,234
2026-08-21Open-market saleCommon Stock951$208$198.2K63,283
2026-08-21Open-market saleCommon Stock1,351$209$282.7K61,932
2026-08-21Open-market saleCommon Stock136$210$28.6K61,796
2026-08-21Open-market saleCommon Stock245$211$51.8K61,551
2026-08-21Open-market saleCommon Stock127$212$26.9K61,424
2026-08-21Open-market saleCommon Stock177$207$36.7K64,247
2026-08-21Open-market saleCommon Stock937$208$195.2K63,310
2026-08-21Open-market saleCommon Stock1,405$209$294.0K61,905
2026-08-21Open-market saleCommon Stock126$210$26.5K61,779
2026-08-21Open-market saleCommon Stock229$211$48.4K61,550
2026-08-21Open-market saleCommon Stock126$212$26.7K61,424
2026-08-21Option exercise/conversionStock Option (Right to Buy)80,000——344,085

Key Dates

DateDescription
2026-08-21Option exercise/conversion (80,000 shares)
2026-08-21Open-market sale (5,128 shares)
2026-08-21Open-market sale (24,917 shares)
2026-08-21Open-market sale (35,938 shares)
2026-08-21Open-market sale (3,813 shares)
2026-08-21Open-market sale (6,583 shares)
2026-08-21Open-market sale (3,621 shares)
2026-08-21Open-market sale (190 shares)
2026-08-21Open-market sale (951 shares)
2026-08-21Open-market sale (1,351 shares)
2026-08-21Open-market sale (136 shares)
2026-08-21Open-market sale (245 shares)
2026-08-21Open-market sale (127 shares)
2026-08-21Open-market sale (177 shares)
2026-08-21Open-market sale (937 shares)
2026-08-21Open-market sale (1,405 shares)
2026-08-21Open-market sale (126 shares)
2026-08-21Open-market sale (229 shares)
2026-08-21Open-market sale (126 shares)
2026-08-21Option exercise/conversion (80,000 shares)

Keywords

insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Mark A Goldsmith

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.